Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Other Non-Current Assets (2022 - 2024)

NewAmsterdam Pharma's Other Non-Current Assets history spans 3 years, with the latest figure at $8000.0 for Q2 2024.

  • For Q2 2024, Other Non-Current Assets changed N/A year-over-year to $8000.0; the TTM value through Jun 2024 reached $8000.0, changed N/A, while the annual FY2023 figure was $35000.0, 77.56% down from the prior year.
  • Other Non-Current Assets for Q2 2024 was $8000.0 at NewAmsterdam Pharma, down from $16000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $156000.0 in Q4 2022 and bottomed at $8000.0 in Q2 2024.
  • The 3-year median for Other Non-Current Assets is $25500.0 (2023), against an average of $53750.0.
  • The largest YoY upside for Other Non-Current Assets was 77.56% in 2023 against a maximum downside of 77.56% in 2023.
  • A 3-year view of Other Non-Current Assets shows it stood at $156000.0 in 2022, then tumbled by 77.56% to $35000.0 in 2023, then tumbled by 77.14% to $8000.0 in 2024.
  • Per Business Quant, the three most recent readings for NAMS's Other Non-Current Assets are $8000.0 (Q2 2024), $16000.0 (Q1 2024), and $35000.0 (Q4 2023).